#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Visuospatial task-related prefrontal activity is correlated with negative symptoms in schizophrenia Control of attention is thought to be specifically impaired in schizophrenia due to abnormal function in the prefrontal cortex (PFC).
1-1	0-12	Visuospatial	_
1-2	13-25	task-related	_
1-3	26-36	prefrontal	_
1-4	37-45	activity	_
1-5	46-48	is	_
1-6	49-59	correlated	_
1-7	60-64	with	_
1-8	65-73	negative	_
1-9	74-82	symptoms	_
1-10	83-85	in	_
1-11	86-99	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	100-107	Control	_
1-13	108-110	of	_
1-14	111-120	attention	_
1-15	121-123	is	_
1-16	124-131	thought	_
1-17	132-134	to	_
1-18	135-137	be	_
1-19	138-150	specifically	_
1-20	151-159	impaired	_
1-21	160-162	in	_
1-22	163-176	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-23	177-180	due	_
1-24	181-183	to	_
1-25	184-192	abnormal	_
1-26	193-201	function	_
1-27	202-204	in	_
1-28	205-208	the	_
1-29	209-219	prefrontal	_
1-30	220-226	cortex	_
1-31	227-228	(	_
1-32	229-232	PFC	_
1-33	233-234	)	_
1-34	235-236	.	_

Text=The PFC plays a critical role in the identification of relevant stimuli and the development of appropriate biases for the identified signals, including selection of an appropriate attentional ‘ zoom ’.
2-1	237-240	The	_
2-2	241-244	PFC	_
2-3	245-250	plays	_
2-4	251-252	a	_
2-5	253-261	critical	_
2-6	262-266	role	_
2-7	267-269	in	_
2-8	270-273	the	_
2-9	274-288	identification	_
2-10	289-291	of	_
2-11	292-300	relevant	_
2-12	301-308	stimuli	_
2-13	309-312	and	_
2-14	313-316	the	_
2-15	317-328	development	_
2-16	329-331	of	_
2-17	332-343	appropriate	_
2-18	344-350	biases	_
2-19	351-354	for	_
2-20	355-358	the	_
2-21	359-369	identified	_
2-22	370-377	signals	_
2-23	378-379	,	_
2-24	380-389	including	_
2-25	390-399	selection	_
2-26	400-402	of	_
2-27	403-405	an	_
2-28	406-417	appropriate	_
2-29	418-429	attentional	_
2-30	430-431	‘	_
2-31	432-436	zoom	_
2-32	437-438	’	_
2-33	439-440	.	_

Text=We examined how demands associated with changes in attentional requirements in a Sustained Attention Task (SAT) may contribute to differences in functional involvement of the PFC and relation to clinical status.
3-1	441-443	We	_
3-2	444-452	examined	_
3-3	453-456	how	_
3-4	457-464	demands	_
3-5	465-475	associated	_
3-6	476-480	with	_
3-7	481-488	changes	_
3-8	489-491	in	_
3-9	492-503	attentional	_
3-10	504-516	requirements	_
3-11	517-519	in	_
3-12	520-521	a	_
3-13	522-531	Sustained	_
3-14	532-541	Attention	_
3-15	542-546	Task	_
3-16	547-548	(	_
3-17	549-552	SAT	_
3-18	553-554	)	_
3-19	555-558	may	_
3-20	559-569	contribute	_
3-21	570-572	to	_
3-22	573-584	differences	_
3-23	585-587	in	_
3-24	588-598	functional	_
3-25	599-610	involvement	_
3-26	611-613	of	_
3-27	614-617	the	_
3-28	618-621	PFC	_
3-29	622-625	and	_
3-30	626-634	relation	_
3-31	635-637	to	_
3-32	638-646	clinical	_
3-33	647-653	status	_
3-34	654-655	.	_

Text=A group of 24 individuals with schizophrenia and 16 healthy controls (N = 40) performed the SAT and a visuospatial condition (vSAT) while activity in the bilateral anterior PFC was monitored using functional Near Infrared Spectroscopy (fNIRS).
4-1	656-657	A	_
4-2	658-663	group	_
4-3	664-666	of	_
4-4	667-669	24	_
4-5	670-681	individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-6	682-686	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-7	687-700	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-8	701-704	and	_
4-9	705-707	16	_
4-10	708-715	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-11	716-724	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-12	725-726	(	_
4-13	727-728	N	_
4-14	729-730	=	_
4-15	731-733	40	_
4-16	734-735	)	_
4-17	736-745	performed	_
4-18	746-749	the	_
4-19	750-753	SAT	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
4-20	754-757	and	_
4-21	758-759	a	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
4-22	760-772	visuospatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
4-23	773-782	condition	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
4-24	783-784	(	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
4-25	785-789	vSAT	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
4-26	790-791	)	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
4-27	792-797	while	_
4-28	798-806	activity	_
4-29	807-809	in	_
4-30	810-813	the	_
4-31	814-823	bilateral	_
4-32	824-832	anterior	_
4-33	833-836	PFC	_
4-34	837-840	was	_
4-35	841-850	monitored	_
4-36	851-856	using	_
4-37	857-867	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
4-38	868-872	Near	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
4-39	873-881	Infrared	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
4-40	882-894	Spectroscopy	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
4-41	895-896	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
4-42	897-902	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
4-43	903-904	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
4-44	905-906	.	_

Text=The results confirm that the right frontopolar region plays a role in control of attention for both patients and healthy controls.
5-1	907-910	The	_
5-2	911-918	results	_
5-3	919-926	confirm	_
5-4	927-931	that	_
5-5	932-935	the	_
5-6	936-941	right	_
5-7	942-953	frontopolar	_
5-8	954-960	region	_
5-9	961-966	plays	_
5-10	967-968	a	_
5-11	969-973	role	_
5-12	974-976	in	_
5-13	977-984	control	_
5-14	985-987	of	_
5-15	988-997	attention	_
5-16	998-1001	for	_
5-17	1002-1006	both	_
5-18	1007-1015	patients	_
5-19	1016-1019	and	_
5-20	1020-1027	healthy	_
5-21	1028-1036	controls	_
5-22	1037-1038	.	_

Text=However, patients with schizophrenia exhibited a general attentional deficit and inefficient right-medial PFC activation.
6-1	1039-1046	However	_
6-2	1047-1048	,	_
6-3	1049-1057	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-4	1058-1062	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-5	1063-1076	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-6	1077-1086	exhibited	_
6-7	1087-1088	a	_
6-8	1089-1096	general	_
6-9	1097-1108	attentional	_
6-10	1109-1116	deficit	_
6-11	1117-1120	and	_
6-12	1121-1132	inefficient	_
6-13	1133-1145	right-medial	_
6-14	1146-1149	PFC	_
6-15	1150-1160	activation	_
6-16	1161-1162	.	_

Text=Additionally, we observed a strong regional association between left Middle Frontal Gyrus (MFG) activity during the vSAT task and the PANSS score driven by the negative symptom subscale.
7-1	1163-1175	Additionally	_
7-2	1176-1177	,	_
7-3	1178-1180	we	_
7-4	1181-1189	observed	_
7-5	1190-1191	a	_
7-6	1192-1198	strong	_
7-7	1199-1207	regional	_
7-8	1208-1219	association	_
7-9	1220-1227	between	_
7-10	1228-1232	left	_
7-11	1233-1239	Middle	_
7-12	1240-1247	Frontal	_
7-13	1248-1253	Gyrus	_
7-14	1254-1255	(	_
7-15	1256-1259	MFG	_
7-16	1260-1261	)	_
7-17	1262-1270	activity	_
7-18	1271-1277	during	_
7-19	1278-1281	the	_
7-20	1282-1286	vSAT	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
7-21	1287-1291	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
7-22	1292-1295	and	_
7-23	1296-1299	the	_
7-24	1300-1305	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
7-25	1306-1311	score	_
7-26	1312-1318	driven	_
7-27	1319-1321	by	_
7-28	1322-1325	the	_
7-29	1326-1334	negative	_
7-30	1335-1342	symptom	_
7-31	1343-1351	subscale	_
7-32	1352-1353	.	_

Text=The presence of aberrant activation differences within the left-MFG region may describe a dysregulation of attentional networks linked to the clinical expression of negative and general symptoms.
8-1	1354-1357	The	_
8-2	1358-1366	presence	_
8-3	1367-1369	of	_
8-4	1370-1378	aberrant	_
8-5	1379-1389	activation	_
8-6	1390-1401	differences	_
8-7	1402-1408	within	_
8-8	1409-1412	the	_
8-9	1413-1421	left-MFG	_
8-10	1422-1428	region	_
8-11	1429-1432	may	_
8-12	1433-1441	describe	_
8-13	1442-1443	a	_
8-14	1444-1457	dysregulation	_
8-15	1458-1460	of	_
8-16	1461-1472	attentional	_
8-17	1473-1481	networks	_
8-18	1482-1488	linked	_
8-19	1489-1491	to	_
8-20	1492-1495	the	_
8-21	1496-1504	clinical	_
8-22	1505-1515	expression	_
8-23	1516-1518	of	_
8-24	1519-1527	negative	_
8-25	1528-1531	and	_
8-26	1532-1539	general	_
8-27	1540-1548	symptoms	_
8-28	1549-1550	.	_

Text=Methods Demographic information Participates in this study consisted of 16 healthy controls (10 female) recruited from the local community and 24 patients (16 female) diagnosed with schizophrenia who were recruited from the Shanghai Mental Health Center in Shanghai, China.
9-1	1551-1558	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-2	1559-1570	Demographic	_
9-3	1571-1582	information	_
9-4	1583-1595	Participates	_
9-5	1596-1598	in	_
9-6	1599-1603	this	_
9-7	1604-1609	study	_
9-8	1610-1619	consisted	_
9-9	1620-1622	of	_
9-10	1623-1625	16	_
9-11	1626-1633	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-12	1634-1642	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-13	1643-1644	(	_
9-14	1645-1647	10	_
9-15	1648-1654	female	_
9-16	1655-1656	)	_
9-17	1657-1666	recruited	_
9-18	1667-1671	from	_
9-19	1672-1675	the	_
9-20	1676-1681	local	_
9-21	1682-1691	community	_
9-22	1692-1695	and	_
9-23	1696-1698	24	_
9-24	1699-1707	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-25	1708-1709	(	_
9-26	1710-1712	16	_
9-27	1713-1719	female	_
9-28	1720-1721	)	_
9-29	1722-1731	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-30	1732-1736	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-31	1737-1750	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-32	1751-1754	who	_
9-33	1755-1759	were	_
9-34	1760-1769	recruited	_
9-35	1770-1774	from	_
9-36	1775-1778	the	_
9-37	1779-1787	Shanghai	_
9-38	1788-1794	Mental	_
9-39	1795-1801	Health	_
9-40	1802-1808	Center	_
9-41	1809-1811	in	_
9-42	1812-1820	Shanghai	_
9-43	1821-1822	,	_
9-44	1823-1828	China	_
9-45	1829-1830	.	_

Text=Participants were all native Chinese over 18 years of age who voluntarily gave informed and written consent to participate in the study.
10-1	1831-1843	Participants	_
10-2	1844-1848	were	_
10-3	1849-1852	all	_
10-4	1853-1859	native	_
10-5	1860-1867	Chinese	_
10-6	1868-1872	over	_
10-7	1873-1875	18	_
10-8	1876-1881	years	_
10-9	1882-1884	of	_
10-10	1885-1888	age	_
10-11	1889-1892	who	_
10-12	1893-1904	voluntarily	_
10-13	1905-1909	gave	_
10-14	1910-1918	informed	_
10-15	1919-1922	and	_
10-16	1923-1930	written	_
10-17	1931-1938	consent	_
10-18	1939-1941	to	_
10-19	1942-1953	participate	_
10-20	1954-1956	in	_
10-21	1957-1960	the	_
10-22	1961-1966	study	_
10-23	1967-1968	.	_

Text=The protocol in this study was reviewed, approved, and carried out according to the guidelines of the IRB of the Shanghai Mental Health.
11-1	1969-1972	The	_
11-2	1973-1981	protocol	_
11-3	1982-1984	in	_
11-4	1985-1989	this	_
11-5	1990-1995	study	_
11-6	1996-1999	was	_
11-7	2000-2008	reviewed	_
11-8	2009-2010	,	_
11-9	2011-2019	approved	_
11-10	2020-2021	,	_
11-11	2022-2025	and	_
11-12	2026-2033	carried	_
11-13	2034-2037	out	_
11-14	2038-2047	according	_
11-15	2048-2050	to	_
11-16	2051-2054	the	_
11-17	2055-2065	guidelines	_
11-18	2066-2068	of	_
11-19	2069-2072	the	_
11-20	2073-2076	IRB	_
11-21	2077-2079	of	_
11-22	2080-2083	the	_
11-23	2084-2092	Shanghai	_
11-24	2093-2099	Mental	_
11-25	2100-2106	Health	_
11-26	2107-2108	.	_

Text=No significant differences were found between group age, education, or gender.
12-1	2109-2111	No	_
12-2	2112-2123	significant	_
12-3	2124-2135	differences	_
12-4	2136-2140	were	_
12-5	2141-2146	found	_
12-6	2147-2154	between	_
12-7	2155-2160	group	_
12-8	2161-2164	age	_
12-9	2165-2166	,	_
12-10	2167-2176	education	_
12-11	2177-2178	,	_
12-12	2179-2181	or	_
12-13	2182-2188	gender	_
12-14	2189-2190	.	_

Text=All subjects participated in the HAM-D 24 Depression Scales and HAM-A Anxiety Scales.
13-1	2191-2194	All	_
13-2	2195-2203	subjects	_
13-3	2204-2216	participated	_
13-4	2217-2219	in	_
13-5	2220-2223	the	_
13-6	2224-2229	HAM-D	http://maven.renci.org/NeuroBridge/neurobridge#dimerMeasurement
13-7	2230-2232	24	_
13-8	2233-2243	Depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
13-9	2244-2250	Scales	http://maven.renci.org/NeuroBridge/neurobridge#Depression
13-10	2251-2254	and	_
13-11	2255-2260	HAM-A	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
13-12	2261-2268	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
13-13	2269-2275	Scales	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
13-14	2276-2277	.	_

Text=Patients were assessed according to the PANSS and its subscales.
14-1	2278-2286	Patients	_
14-2	2287-2291	were	_
14-3	2292-2300	assessed	_
14-4	2301-2310	according	_
14-5	2311-2313	to	_
14-6	2314-2317	the	_
14-7	2318-2323	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
14-8	2324-2327	and	_
14-9	2328-2331	its	_
14-10	2332-2341	subscales	_
14-11	2342-2343	.	_

Text=Patients scored significantly higher than controls on HAM Depression (p = 0.001) and Anxiety scores (p <0.01) respectively.
15-1	2344-2352	Patients	_
15-2	2353-2359	scored	_
15-3	2360-2373	significantly	_
15-4	2374-2380	higher	_
15-5	2381-2385	than	_
15-6	2386-2394	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-7	2395-2397	on	_
15-8	2398-2401	HAM	http://maven.renci.org/NeuroBridge/neurobridge#Depression
15-9	2402-2412	Depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
15-10	2413-2414	(	_
15-11	2415-2416	p	_
15-12	2417-2418	=	_
15-13	2419-2424	0.001	_
15-14	2425-2426	)	_
15-15	2427-2430	and	_
15-16	2431-2438	Anxiety	_
15-17	2439-2445	scores	_
15-18	2446-2447	(	_
15-19	2448-2449	p	_
15-20	2450-2451	<	_
15-21	2452-2456	0.01	_
15-22	2457-2458	)	_
15-23	2459-2471	respectively	_
15-24	2472-2473	.	_

Text=Demographic information is presented in Table 1.
16-1	2474-2485	Demographic	_
16-2	2486-2497	information	_
16-3	2498-2500	is	_
16-4	2501-2510	presented	_
16-5	2511-2513	in	_
16-6	2514-2519	Table	_
16-7	2520-2521	1	_
16-8	2522-2523	.	_

Text=Detailed antipsychotic medication at time of testing for participants is listed in Supplementary Table A2.
17-1	2524-2532	Detailed	_
17-2	2533-2546	antipsychotic	_
17-3	2547-2557	medication	_
17-4	2558-2560	at	_
17-5	2561-2565	time	_
17-6	2566-2568	of	_
17-7	2569-2576	testing	_
17-8	2577-2580	for	_
17-9	2581-2593	participants	_
17-10	2594-2596	is	_
17-11	2597-2603	listed	_
17-12	2604-2606	in	_
17-13	2607-2620	Supplementary	_
17-14	2621-2626	Table	_
17-15	2627-2629	A2	_
17-16	2630-2631	.	_

Text=Experimental procedure The SAT was constructed using a custom OpenGL program based on the methodology detailed in Demeter et al ..
18-1	2632-2644	Experimental	_
18-2	2645-2654	procedure	_
18-3	2655-2658	The	_
18-4	2659-2662	SAT	_
18-5	2663-2666	was	_
18-6	2667-2678	constructed	_
18-7	2679-2684	using	_
18-8	2685-2686	a	_
18-9	2687-2693	custom	_
18-10	2694-2700	OpenGL	_
18-11	2701-2708	program	_
18-12	2709-2714	based	_
18-13	2715-2717	on	_
18-14	2718-2721	the	_
18-15	2722-2733	methodology	_
18-16	2734-2742	detailed	_
18-17	2743-2745	in	_
18-18	2746-2753	Demeter	_
18-19	2754-2756	et	_
18-20	2757-2759	al	_
18-21	2760-2762	..	_

Text=Participants were asked to monitor a silver screen (Lum 170) for a signal consisting of the appearance of a small gray square (Lum 107) in the center of the screen for varying durations of 20, 30 or 50 ms (corresponding to 1, 2, and 3 frames at a typical refresh rate of 60 Hz).
19-1	2763-2775	Participants	_
19-2	2776-2780	were	_
19-3	2781-2786	asked	_
19-4	2787-2789	to	_
19-5	2790-2797	monitor	_
19-6	2798-2799	a	_
19-7	2800-2806	silver	_
19-8	2807-2813	screen	_
19-9	2814-2815	(	_
19-10	2816-2819	Lum	_
19-11	2820-2823	170	_
19-12	2824-2825	)	_
19-13	2826-2829	for	_
19-14	2830-2831	a	_
19-15	2832-2838	signal	_
19-16	2839-2849	consisting	_
19-17	2850-2852	of	_
19-18	2853-2856	the	_
19-19	2857-2867	appearance	_
19-20	2868-2870	of	_
19-21	2871-2872	a	_
19-22	2873-2878	small	_
19-23	2879-2883	gray	_
19-24	2884-2890	square	_
19-25	2891-2892	(	_
19-26	2893-2896	Lum	_
19-27	2897-2900	107	_
19-28	2901-2902	)	_
19-29	2903-2905	in	_
19-30	2906-2909	the	_
19-31	2910-2916	center	_
19-32	2917-2919	of	_
19-33	2920-2923	the	_
19-34	2924-2930	screen	_
19-35	2931-2934	for	_
19-36	2935-2942	varying	_
19-37	2943-2952	durations	_
19-38	2953-2955	of	_
19-39	2956-2958	20	_
19-40	2959-2960	,	_
19-41	2961-2963	30	_
19-42	2964-2966	or	_
19-43	2967-2969	50	_
19-44	2970-2972	ms	_
19-45	2973-2974	(	_
19-46	2975-2988	corresponding	_
19-47	2989-2991	to	_
19-48	2992-2993	1	_
19-49	2994-2995	,	_
19-50	2996-2997	2	_
19-51	2998-2999	,	_
19-52	3000-3003	and	_
19-53	3004-3005	3	_
19-54	3006-3012	frames	_
19-55	3013-3015	at	_
19-56	3016-3017	a	_
19-57	3018-3025	typical	_
19-58	3026-3033	refresh	_
19-59	3034-3038	rate	_
19-60	3039-3041	of	_
19-61	3042-3044	60	_
19-62	3045-3047	Hz	_
19-63	3048-3049	)	_
19-64	3050-3051	.	_

Text=Monitoring times before signal/non-signal presentation were varied pseudo randomly at a 1, 2, or 3 s inter-trial interval, and signal frequency was roughly 50% (Fig.
20-1	3052-3062	Monitoring	_
20-2	3063-3068	times	_
20-3	3069-3075	before	_
20-4	3076-3093	signal/non-signal	_
20-5	3094-3106	presentation	_
20-6	3107-3111	were	_
20-7	3112-3118	varied	_
20-8	3119-3125	pseudo	_
20-9	3126-3134	randomly	_
20-10	3135-3137	at	_
20-11	3138-3139	a	_
20-12	3140-3141	1	_
20-13	3142-3143	,	_
20-14	3144-3145	2	_
20-15	3146-3147	,	_
20-16	3148-3150	or	_
20-17	3151-3152	3	_
20-18	3153-3154	s	_
20-19	3155-3166	inter-trial	_
20-20	3167-3175	interval	_
20-21	3176-3177	,	_
20-22	3178-3181	and	_
20-23	3182-3188	signal	_
20-24	3189-3198	frequency	_
20-25	3199-3202	was	_
20-26	3203-3210	roughly	_
20-27	3211-3213	50	_
20-28	3214-3215	%	_
20-29	3216-3217	(	_
20-30	3218-3221	Fig	_
20-31	3222-3223	.	_

Text=1).
21-1	3224-3225	1	_
21-2	3226-3227	)	_
21-3	3228-3229	.	_

Text=100 ms following the appearance or non-appearance of the signal, the subject was informed by an audio cue and asked to denote whether the event was a signal or non-signal using the left and right mouse click respectively.
22-1	3230-3233	100	_
22-2	3234-3236	ms	_
22-3	3237-3246	following	_
22-4	3247-3250	the	_
22-5	3251-3261	appearance	_
22-6	3262-3264	or	_
22-7	3265-3279	non-appearance	_
22-8	3280-3282	of	_
22-9	3283-3286	the	_
22-10	3287-3293	signal	_
22-11	3294-3295	,	_
22-12	3296-3299	the	_
22-13	3300-3307	subject	_
22-14	3308-3311	was	_
22-15	3312-3320	informed	_
22-16	3321-3323	by	_
22-17	3324-3326	an	_
22-18	3327-3332	audio	_
22-19	3333-3336	cue	_
22-20	3337-3340	and	_
22-21	3341-3346	asked	_
22-22	3347-3349	to	_
22-23	3350-3356	denote	_
22-24	3357-3364	whether	_
22-25	3365-3368	the	_
22-26	3369-3374	event	_
22-27	3375-3378	was	_
22-28	3379-3380	a	_
22-29	3381-3387	signal	_
22-30	3388-3390	or	_
22-31	3391-3401	non-signal	_
22-32	3402-3407	using	_
22-33	3408-3411	the	_
22-34	3412-3416	left	_
22-35	3417-3420	and	_
22-36	3421-3426	right	_
22-37	3427-3432	mouse	_
22-38	3433-3438	click	_
22-39	3439-3451	respectively	_
22-40	3452-3453	.	_

Text=The subject then was given 1500 ms to classify the event.
23-1	3454-3457	The	_
23-2	3458-3465	subject	_
23-3	3466-3470	then	_
23-4	3471-3474	was	_
23-5	3475-3480	given	_
23-6	3481-3485	1500	_
23-7	3486-3488	ms	_
23-8	3489-3491	to	_
23-9	3492-3500	classify	_
23-10	3501-3504	the	_
23-11	3505-3510	event	_
23-12	3511-3512	.	_

Text=Correct classifications were immediately given an audio feedback, while incorrect trials receive no feedback.
24-1	3513-3520	Correct	_
24-2	3521-3536	classifications	_
24-3	3537-3541	were	_
24-4	3542-3553	immediately	_
24-5	3554-3559	given	_
24-6	3560-3562	an	_
24-7	3563-3568	audio	_
24-8	3569-3577	feedback	_
24-9	3578-3579	,	_
24-10	3580-3585	while	_
24-11	3586-3595	incorrect	_
24-12	3596-3602	trials	_
24-13	3603-3610	receive	_
24-14	3611-3613	no	_
24-15	3614-3622	feedback	_
24-16	3623-3624	.	_

Text=Each task block was preceded by a 30 second resting period and lasted for approximately 120 seconds with approximately 42 stimulus trials in each task block.
25-1	3625-3629	Each	_
25-2	3630-3634	task	_
25-3	3635-3640	block	_
25-4	3641-3644	was	_
25-5	3645-3653	preceded	_
25-6	3654-3656	by	_
25-7	3657-3658	a	_
25-8	3659-3661	30	_
25-9	3662-3668	second	_
25-10	3669-3676	resting	_
25-11	3677-3683	period	_
25-12	3684-3687	and	_
25-13	3688-3694	lasted	_
25-14	3695-3698	for	_
25-15	3699-3712	approximately	_
25-16	3713-3716	120	_
25-17	3717-3724	seconds	_
25-18	3725-3729	with	_
25-19	3730-3743	approximately	_
25-20	3744-3746	42	_
25-21	3747-3755	stimulus	_
25-22	3756-3762	trials	_
25-23	3763-3765	in	_
25-24	3766-3770	each	_
25-25	3771-3775	task	_
25-26	3776-3781	block	_
25-27	3782-3783	.	_

Text=Following the end of each block, a cumulative performance metric is displayed to the subject.
26-1	3784-3793	Following	_
26-2	3794-3797	the	_
26-3	3798-3801	end	_
26-4	3802-3804	of	_
26-5	3805-3809	each	_
26-6	3810-3815	block	_
26-7	3816-3817	,	_
26-8	3818-3819	a	_
26-9	3820-3830	cumulative	_
26-10	3831-3842	performance	_
26-11	3843-3849	metric	_
26-12	3850-3852	is	_
26-13	3853-3862	displayed	_
26-14	3863-3865	to	_
26-15	3866-3869	the	_
26-16	3870-3877	subject	_
26-17	3878-3879	.	_

Text=Each subject performed a total of 4 blocks, with two repetitions for each task type (vSAT & SAT).
27-1	3880-3884	Each	_
27-2	3885-3892	subject	_
27-3	3893-3902	performed	_
27-4	3903-3904	a	_
27-5	3905-3910	total	_
27-6	3911-3913	of	_
27-7	3914-3915	4	_
27-8	3916-3922	blocks	_
27-9	3923-3924	,	_
27-10	3925-3929	with	_
27-11	3930-3933	two	_
27-12	3934-3945	repetitions	_
27-13	3946-3949	for	_
27-14	3950-3954	each	_
27-15	3955-3959	task	_
27-16	3960-3964	type	_
27-17	3965-3966	(	_
27-18	3967-3971	vSAT	_
27-19	3972-3973	&	_
27-20	3974-3977	SAT	_
27-21	3978-3979	)	_
27-22	3980-3981	.	_

Text=A modification to the SAT, detailed here as vSAT, was used to introduce broadened attentional focus through the introduction of a visuospatial component.
28-1	3982-3983	A	_
28-2	3984-3996	modification	_
28-3	3997-3999	to	_
28-4	4000-4003	the	_
28-5	4004-4007	SAT	_
28-6	4008-4009	,	_
28-7	4010-4018	detailed	_
28-8	4019-4023	here	_
28-9	4024-4026	as	_
28-10	4027-4031	vSAT	_
28-11	4032-4033	,	_
28-12	4034-4037	was	_
28-13	4038-4042	used	_
28-14	4043-4045	to	_
28-15	4046-4055	introduce	_
28-16	4056-4065	broadened	_
28-17	4066-4077	attentional	_
28-18	4078-4083	focus	_
28-19	4084-4091	through	_
28-20	4092-4095	the	_
28-21	4096-4108	introduction	_
28-22	4109-4111	of	_
28-23	4112-4113	a	_
28-24	4114-4126	visuospatial	_
28-25	4127-4136	component	_
28-26	4137-4138	.	_

Text=The task in vSAT is similar to the VSL-SAT task described by Demeter et al.
29-1	4139-4142	The	_
29-2	4143-4147	task	_
29-3	4148-4150	in	_
29-4	4151-4155	vSAT	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
29-5	4156-4158	is	_
29-6	4159-4166	similar	_
29-7	4167-4169	to	_
29-8	4170-4173	the	_
29-9	4174-4181	VSL-SAT	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
29-10	4182-4186	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
29-11	4187-4196	described	_
29-12	4197-4199	by	_
29-13	4200-4207	Demeter	_
29-14	4208-4210	et	_
29-15	4211-4213	al	_
29-16	4214-4215	.	_

Text=with two modifications intended to increase task difficulty by requiring additional attentional resources.
30-1	4216-4220	with	_
30-2	4221-4224	two	_
30-3	4225-4238	modifications	_
30-4	4239-4247	intended	_
30-5	4248-4250	to	_
30-6	4251-4259	increase	_
30-7	4260-4264	task	_
30-8	4265-4275	difficulty	_
30-9	4276-4278	by	_
30-10	4279-4288	requiring	_
30-11	4289-4299	additional	_
30-12	4300-4311	attentional	_
30-13	4312-4321	resources	_
30-14	4322-4323	.	_

Text=Contrast between the silver background and the signal was reduced by using a lighter gray block (Lum 155) to reduce the prominence of the signal.
31-1	4324-4332	Contrast	_
31-2	4333-4340	between	_
31-3	4341-4344	the	_
31-4	4345-4351	silver	_
31-5	4352-4362	background	_
31-6	4363-4366	and	_
31-7	4367-4370	the	_
31-8	4371-4377	signal	_
31-9	4378-4381	was	_
31-10	4382-4389	reduced	_
31-11	4390-4392	by	_
31-12	4393-4398	using	_
31-13	4399-4400	a	_
31-14	4401-4408	lighter	_
31-15	4409-4413	gray	_
31-16	4414-4419	block	_
31-17	4420-4421	(	_
31-18	4422-4425	Lum	_
31-19	4426-4429	155	_
31-20	4430-4431	)	_
31-21	4432-4434	to	_
31-22	4435-4441	reduce	_
31-23	4442-4445	the	_
31-24	4446-4456	prominence	_
31-25	4457-4459	of	_
31-26	4460-4463	the	_
31-27	4464-4470	signal	_
31-28	4471-4472	.	_

Text=Additionally, signal location was pseudo randomly presented at one of 5 separate locations on the screen (Center, Top-Left, Top-Right, Bottom-Right, and Bottom-Left).
32-1	4473-4485	Additionally	_
32-2	4486-4487	,	_
32-3	4488-4494	signal	_
32-4	4495-4503	location	_
32-5	4504-4507	was	_
32-6	4508-4514	pseudo	_
32-7	4515-4523	randomly	_
32-8	4524-4533	presented	_
32-9	4534-4536	at	_
32-10	4537-4540	one	_
32-11	4541-4543	of	_
32-12	4544-4545	5	_
32-13	4546-4554	separate	_
32-14	4555-4564	locations	_
32-15	4565-4567	on	_
32-16	4568-4571	the	_
32-17	4572-4578	screen	_
32-18	4579-4580	(	_
32-19	4581-4587	Center	_
32-20	4588-4589	,	_
32-21	4590-4598	Top-Left	_
32-22	4599-4600	,	_
32-23	4601-4610	Top-Right	_
32-24	4611-4612	,	_
32-25	4613-4625	Bottom-Right	_
32-26	4626-4627	,	_
32-27	4628-4631	and	_
32-28	4632-4643	Bottom-Left	_
32-29	4644-4645	)	_
32-30	4646-4647	.	_

Text=An illustration describing the protocol is presented in Fig.
33-1	4648-4650	An	_
33-2	4651-4663	illustration	_
33-3	4664-4674	describing	_
33-4	4675-4678	the	_
33-5	4679-4687	protocol	_
33-6	4688-4690	is	_
33-7	4691-4700	presented	_
33-8	4701-4703	in	_
33-9	4704-4707	Fig	_
33-10	4708-4709	.	_

Text=1.
34-1	4710-4711	1	_
34-2	4712-4713	.	_

Text=Task performance was assessed using the SAT score, calculated using the methodology defined by Demeter et al ..
35-1	4714-4718	Task	_
35-2	4719-4730	performance	_
35-3	4731-4734	was	_
35-4	4735-4743	assessed	_
35-5	4744-4749	using	_
35-6	4750-4753	the	_
35-7	4754-4757	SAT	_
35-8	4758-4763	score	_
35-9	4764-4765	,	_
35-10	4766-4776	calculated	_
35-11	4777-4782	using	_
35-12	4783-4786	the	_
35-13	4787-4798	methodology	_
35-14	4799-4806	defined	_
35-15	4807-4809	by	_
35-16	4810-4817	Demeter	_
35-17	4818-4820	et	_
35-18	4821-4823	al	_
35-19	4824-4826	..	_

Text=This metric, which had been previously identified as the “ Vigilance Index ”, was identified as being comparable to other signal-detection measurements, namely d-prime, and uninfluenced by errors of omission.
36-1	4827-4831	This	_
36-2	4832-4838	metric	_
36-3	4839-4840	,	_
36-4	4841-4846	which	_
36-5	4847-4850	had	_
36-6	4851-4855	been	_
36-7	4856-4866	previously	_
36-8	4867-4877	identified	_
36-9	4878-4880	as	_
36-10	4881-4884	the	_
36-11	4885-4886	“	_
36-12	4887-4896	Vigilance	_
36-13	4897-4902	Index	_
36-14	4903-4904	”	_
36-15	4905-4906	,	_
36-16	4907-4910	was	_
36-17	4911-4921	identified	_
36-18	4922-4924	as	_
36-19	4925-4930	being	_
36-20	4931-4941	comparable	_
36-21	4942-4944	to	_
36-22	4945-4950	other	_
36-23	4951-4967	signal-detection	_
36-24	4968-4980	measurements	_
36-25	4981-4982	,	_
36-26	4983-4989	namely	_
36-27	4990-4997	d-prime	_
36-28	4998-4999	,	_
36-29	5000-5003	and	_
36-30	5004-5016	uninfluenced	_
36-31	5017-5019	by	_
36-32	5020-5026	errors	_
36-33	5027-5029	of	_
36-34	5030-5038	omission	_
36-35	5039-5040	.	_

Text=SAT score is defined aswhere Hits mean probability of correct signal/non-signal classification and False Alarms denote probability of incorrect signal/non-signal classification.
37-1	5041-5044	SAT	_
37-2	5045-5050	score	_
37-3	5051-5053	is	_
37-4	5054-5061	defined	_
37-5	5062-5069	aswhere	_
37-6	5070-5074	Hits	_
37-7	5075-5079	mean	_
37-8	5080-5091	probability	_
37-9	5092-5094	of	_
37-10	5095-5102	correct	_
37-11	5103-5120	signal/non-signal	_
37-12	5121-5135	classification	_
37-13	5136-5139	and	_
37-14	5140-5145	False	_
37-15	5146-5152	Alarms	_
37-16	5153-5159	denote	_
37-17	5160-5171	probability	_
37-18	5172-5174	of	_
37-19	5175-5184	incorrect	_
37-20	5185-5202	signal/non-signal	_
37-21	5203-5217	classification	_
37-22	5218-5219	.	_

Text=SAT score ranges from −1 to + 1, with +1 indicating correct classification of all signal/non-signal events and −1 indicating that all responses were false alarms.
38-1	5220-5223	SAT	_
38-2	5224-5229	score	_
38-3	5230-5236	ranges	_
38-4	5237-5241	from	_
38-5	5242-5244	−1	_
38-6	5245-5247	to	_
38-7	5248-5249	+	_
38-8	5250-5251	1	_
38-9	5252-5253	,	_
38-10	5254-5258	with	_
38-11	5259-5261	+1	_
38-12	5262-5272	indicating	_
38-13	5273-5280	correct	_
38-14	5281-5295	classification	_
38-15	5296-5298	of	_
38-16	5299-5302	all	_
38-17	5303-5320	signal/non-signal	_
38-18	5321-5327	events	_
38-19	5328-5331	and	_
38-20	5332-5334	−1	_
38-21	5335-5345	indicating	_
38-22	5346-5350	that	_
38-23	5351-5354	all	_
38-24	5355-5364	responses	_
38-25	5365-5369	were	_
38-26	5370-5375	false	_
38-27	5376-5382	alarms	_
38-28	5383-5384	.	_

Text=Additionally, we calculated the Score Difference as a measure of performance changes associated with Task Type manipulation.
39-1	5385-5397	Additionally	_
39-2	5398-5399	,	_
39-3	5400-5402	we	_
39-4	5403-5413	calculated	_
39-5	5414-5417	the	_
39-6	5418-5423	Score	_
39-7	5424-5434	Difference	_
39-8	5435-5437	as	_
39-9	5438-5439	a	_
39-10	5440-5447	measure	_
39-11	5448-5450	of	_
39-12	5451-5462	performance	_
39-13	5463-5470	changes	_
39-14	5471-5481	associated	_
39-15	5482-5486	with	_
39-16	5487-5491	Task	_
39-17	5492-5496	Type	_
39-18	5497-5509	manipulation	_
39-19	5510-5511	.	_

Text=Score Difference (ScoreDiffvSAT) was calculated as the difference between Score on the vSAT task and the subject ’ s mean SAT score.
40-1	5512-5517	Score	_
40-2	5518-5528	Difference	_
40-3	5529-5530	(	_
40-4	5531-5544	ScoreDiffvSAT	_
40-5	5545-5546	)	_
40-6	5547-5550	was	_
40-7	5551-5561	calculated	_
40-8	5562-5564	as	_
40-9	5565-5568	the	_
40-10	5569-5579	difference	_
40-11	5580-5587	between	_
40-12	5588-5593	Score	_
40-13	5594-5596	on	_
40-14	5597-5600	the	_
40-15	5601-5605	vSAT	_
40-16	5606-5610	task	_
40-17	5611-5614	and	_
40-18	5615-5618	the	_
40-19	5619-5626	subject	_
40-20	5627-5628	’	_
40-21	5629-5630	s	_
40-22	5631-5635	mean	_
40-23	5636-5639	SAT	_
40-24	5640-5645	score	_
40-25	5646-5647	.	_

Text=Larger values of ScoreDiffvSAT are undesirable and would indicate large performance decreases associated with task type variation and increased sensitivity to attentional demand manipulation.
41-1	5648-5654	Larger	_
41-2	5655-5661	values	_
41-3	5662-5664	of	_
41-4	5665-5678	ScoreDiffvSAT	_
41-5	5679-5682	are	_
41-6	5683-5694	undesirable	_
41-7	5695-5698	and	_
41-8	5699-5704	would	_
41-9	5705-5713	indicate	_
41-10	5714-5719	large	_
41-11	5720-5731	performance	_
41-12	5732-5741	decreases	_
41-13	5742-5752	associated	_
41-14	5753-5757	with	_
41-15	5758-5762	task	_
41-16	5763-5767	type	_
41-17	5768-5777	variation	_
41-18	5778-5781	and	_
41-19	5782-5791	increased	_
41-20	5792-5803	sensitivity	_
41-21	5804-5806	to	_
41-22	5807-5818	attentional	_
41-23	5819-5825	demand	_
41-24	5826-5838	manipulation	_
41-25	5839-5840	.	_

Text=fNIRS data acquisition and processing Neuroimaging data was collected for 16 channels at 2 Hz from the anterior PFC (BA 10/46) using the fNIR1100 imager (fNIR Devices, Potomac, MD, USA) using COBI Studio as described in detail at Ayaz et al ..
42-1	5841-5846	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
42-2	5847-5851	data	_
42-3	5852-5863	acquisition	_
42-4	5864-5867	and	_
42-5	5868-5878	processing	_
42-6	5879-5891	Neuroimaging	_
42-7	5892-5896	data	_
42-8	5897-5900	was	_
42-9	5901-5910	collected	_
42-10	5911-5914	for	_
42-11	5915-5917	16	_
42-12	5918-5926	channels	_
42-13	5927-5929	at	_
42-14	5930-5931	2	_
42-15	5932-5934	Hz	_
42-16	5935-5939	from	_
42-17	5940-5943	the	_
42-18	5944-5952	anterior	_
42-19	5953-5956	PFC	_
42-20	5957-5958	(	_
42-21	5959-5961	BA	_
42-22	5962-5967	10/46	_
42-23	5968-5969	)	_
42-24	5970-5975	using	_
42-25	5976-5979	the	_
42-26	5980-5988	fNIR1100	_
42-27	5989-5995	imager	_
42-28	5996-5997	(	_
42-29	5998-6002	fNIR	_
42-30	6003-6010	Devices	_
42-31	6011-6012	,	_
42-32	6013-6020	Potomac	_
42-33	6021-6022	,	_
42-34	6023-6025	MD	_
42-35	6026-6027	,	_
42-36	6028-6031	USA	_
42-37	6032-6033	)	_
42-38	6034-6039	using	_
42-39	6040-6044	COBI	_
42-40	6045-6051	Studio	_
42-41	6052-6054	as	_
42-42	6055-6064	described	_
42-43	6065-6067	in	_
42-44	6068-6074	detail	_
42-45	6075-6077	at	_
42-46	6078-6082	Ayaz	_
42-47	6083-6085	et	_
42-48	6086-6088	al	_
42-49	6089-6091	..	_

Text=The fNIRS sensor was symmetrically centered and in line with Fp1 and Fp2 of the international 10–20 system on the subject ’ s forehead.
43-1	6092-6095	The	_
43-2	6096-6101	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
43-3	6102-6108	sensor	_
43-4	6109-6112	was	_
43-5	6113-6126	symmetrically	_
43-6	6127-6135	centered	_
43-7	6136-6139	and	_
43-8	6140-6142	in	_
43-9	6143-6147	line	_
43-10	6148-6152	with	_
43-11	6153-6156	Fp1	_
43-12	6157-6160	and	_
43-13	6161-6164	Fp2	_
43-14	6165-6167	of	_
43-15	6168-6171	the	_
43-16	6172-6185	international	_
43-17	6186-6191	10–20	_
43-18	6192-6198	system	_
43-19	6199-6201	on	_
43-20	6202-6205	the	_
43-21	6206-6213	subject	_
43-22	6214-6215	’	_
43-23	6216-6217	s	_
43-24	6218-6226	forehead	_
43-25	6227-6228	.	_

Text=The light intensity and detector gain were adjusted during setup to obtain sufficiently high but unsaturated intensity signals according to subject and environmental conditions.
44-1	6229-6232	The	_
44-2	6233-6238	light	_
44-3	6239-6248	intensity	_
44-4	6249-6252	and	_
44-5	6253-6261	detector	_
44-6	6262-6266	gain	_
44-7	6267-6271	were	_
44-8	6272-6280	adjusted	_
44-9	6281-6287	during	_
44-10	6288-6293	setup	_
44-11	6294-6296	to	_
44-12	6297-6303	obtain	_
44-13	6304-6316	sufficiently	_
44-14	6317-6321	high	_
44-15	6322-6325	but	_
44-16	6326-6337	unsaturated	_
44-17	6338-6347	intensity	_
44-18	6348-6355	signals	_
44-19	6356-6365	according	_
44-20	6366-6368	to	_
44-21	6369-6376	subject	_
44-22	6377-6380	and	_
44-23	6381-6394	environmental	_
44-24	6395-6405	conditions	_
44-25	6406-6407	.	_

Text=Channels were visually inspected for signal validity and the signal quality of individual task blocks was assessed and automatically rejected using the criteria adapted from Takizawa et al ..
45-1	6408-6416	Channels	_
45-2	6417-6421	were	_
45-3	6422-6430	visually	_
45-4	6431-6440	inspected	_
45-5	6441-6444	for	_
45-6	6445-6451	signal	_
45-7	6452-6460	validity	_
45-8	6461-6464	and	_
45-9	6465-6468	the	_
45-10	6469-6475	signal	_
45-11	6476-6483	quality	_
45-12	6484-6486	of	_
45-13	6487-6497	individual	_
45-14	6498-6502	task	_
45-15	6503-6509	blocks	_
45-16	6510-6513	was	_
45-17	6514-6522	assessed	_
45-18	6523-6526	and	_
45-19	6527-6540	automatically	_
45-20	6541-6549	rejected	_
45-21	6550-6555	using	_
45-22	6556-6559	the	_
45-23	6560-6568	criteria	_
45-24	6569-6576	adapted	_
45-25	6577-6581	from	_
45-26	6582-6590	Takizawa	_
45-27	6591-6593	et	_
45-28	6594-6596	al	_
45-29	6597-6599	..	_

Text=Surviving blocks were screened for motion artifacts using the SMAR algorithm, and a bandpass filter (0.008–0.25 Hz) was used to reduce high frequency noise associated with respiratory or cardiac function and remove signal drift.
46-1	6600-6609	Surviving	_
46-2	6610-6616	blocks	_
46-3	6617-6621	were	_
46-4	6622-6630	screened	_
46-5	6631-6634	for	_
46-6	6635-6641	motion	_
46-7	6642-6651	artifacts	_
46-8	6652-6657	using	_
46-9	6658-6661	the	_
46-10	6662-6666	SMAR	_
46-11	6667-6676	algorithm	_
46-12	6677-6678	,	_
46-13	6679-6682	and	_
46-14	6683-6684	a	_
46-15	6685-6693	bandpass	_
46-16	6694-6700	filter	_
46-17	6701-6702	(	_
46-18	6703-6713	0.008–0.25	_
46-19	6714-6716	Hz	_
46-20	6717-6718	)	_
46-21	6719-6722	was	_
46-22	6723-6727	used	_
46-23	6728-6730	to	_
46-24	6731-6737	reduce	_
46-25	6738-6742	high	_
46-26	6743-6752	frequency	_
46-27	6753-6758	noise	_
46-28	6759-6769	associated	_
46-29	6770-6774	with	_
46-30	6775-6786	respiratory	_
46-31	6787-6789	or	_
46-32	6790-6797	cardiac	_
46-33	6798-6806	function	_
46-34	6807-6810	and	_
46-35	6811-6817	remove	_
46-36	6818-6824	signal	_
46-37	6825-6830	drift	_
46-38	6831-6832	.	_

Text=Physiological parameters are calculated using the modified Beer-Lambert Law using the 5 seconds before task initiation as a baseline period.
47-1	6833-6846	Physiological	_
47-2	6847-6857	parameters	_
47-3	6858-6861	are	_
47-4	6862-6872	calculated	_
47-5	6873-6878	using	_
47-6	6879-6882	the	_
47-7	6883-6891	modified	_
47-8	6892-6904	Beer-Lambert	_
47-9	6905-6908	Law	_
47-10	6909-6914	using	_
47-11	6915-6918	the	_
47-12	6919-6920	5	_
47-13	6921-6928	seconds	_
47-14	6929-6935	before	_
47-15	6936-6940	task	_
47-16	6941-6951	initiation	_
47-17	6952-6954	as	_
47-18	6955-6956	a	_
47-19	6957-6965	baseline	_
47-20	6966-6972	period	_
47-21	6973-6974	.	_

Text=Extracted measures are reported as the fNIRS biomarkers of [HbO], [HbR], and an estimate of relative change in Oxygen availability [Oxy] (calculated as the difference between [HbO] and [HbR]).
48-1	6975-6984	Extracted	_
48-2	6985-6993	measures	_
48-3	6994-6997	are	_
48-4	6998-7006	reported	_
48-5	7007-7009	as	_
48-6	7010-7013	the	_
48-7	7014-7019	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
48-8	7020-7030	biomarkers	_
48-9	7031-7033	of	_
48-10	7034-7035	[	_
48-11	7036-7039	HbO	_
48-12	7040-7041	]	_
48-13	7042-7043	,	_
48-14	7044-7045	[	_
48-15	7046-7049	HbR	_
48-16	7050-7051	]	_
48-17	7052-7053	,	_
48-18	7054-7057	and	_
48-19	7058-7060	an	_
48-20	7061-7069	estimate	_
48-21	7070-7072	of	_
48-22	7073-7081	relative	_
48-23	7082-7088	change	_
48-24	7089-7091	in	_
48-25	7092-7098	Oxygen	_
48-26	7099-7111	availability	_
48-27	7112-7113	[	_
48-28	7114-7117	Oxy	_
48-29	7118-7119	]	_
48-30	7120-7121	(	_
48-31	7122-7132	calculated	_
48-32	7133-7135	as	_
48-33	7136-7139	the	_
48-34	7140-7150	difference	_
48-35	7151-7158	between	_
48-36	7159-7160	[	_
48-37	7161-7164	HbO	_
48-38	7165-7166	]	_
48-39	7167-7170	and	_
48-40	7171-7172	[	_
48-41	7173-7176	HbR	_
48-42	7177-7178	]	_
48-43	7179-7180	)	_
48-44	7181-7182	.	_

Text=The mean change from the pre-task baseline in fNIRS biomarkers ([HbO], [HbR], and [Oxy]) was assessed as the outcome of interest for statistical tests.
49-1	7183-7186	The	_
49-2	7187-7191	mean	_
49-3	7192-7198	change	_
49-4	7199-7203	from	_
49-5	7204-7207	the	_
49-6	7208-7216	pre-task	_
49-7	7217-7225	baseline	_
49-8	7226-7228	in	_
49-9	7229-7234	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
49-10	7235-7245	biomarkers	_
49-11	7246-7247	(	_
49-12	7248-7249	[	_
49-13	7250-7253	HbO	_
49-14	7254-7255	]	_
49-15	7256-7257	,	_
49-16	7258-7259	[	_
49-17	7260-7263	HbR	_
49-18	7264-7265	]	_
49-19	7266-7267	,	_
49-20	7268-7271	and	_
49-21	7272-7273	[	_
49-22	7274-7277	Oxy	_
49-23	7278-7279	]	_
49-24	7280-7281	)	_
49-25	7282-7285	was	_
49-26	7286-7294	assessed	_
49-27	7295-7297	as	_
49-28	7298-7301	the	_
49-29	7302-7309	outcome	_
49-30	7310-7312	of	_
49-31	7313-7321	interest	_
49-32	7322-7325	for	_
49-33	7326-7337	statistical	_
49-34	7338-7343	tests	_
49-35	7344-7345	.	_

Text=Parametric plots for visualization purposes were registered to a virtual brain according to the methodology described in Ayaz et al ..
50-1	7346-7356	Parametric	_
50-2	7357-7362	plots	_
50-3	7363-7366	for	_
50-4	7367-7380	visualization	_
50-5	7381-7389	purposes	_
50-6	7390-7394	were	_
50-7	7395-7405	registered	_
50-8	7406-7408	to	_
50-9	7409-7410	a	_
50-10	7411-7418	virtual	_
50-11	7419-7424	brain	_
50-12	7425-7434	according	_
50-13	7435-7437	to	_
50-14	7438-7441	the	_
50-15	7442-7453	methodology	_
50-16	7454-7463	described	_
50-17	7464-7466	in	_
50-18	7467-7471	Ayaz	_
50-19	7472-7474	et	_
50-20	7475-7477	al	_
50-21	7478-7480	..	_

Text=Estimated underlying gyri and Brodmann ’ s areas for Optodes 1–16 are described in the Supplementary Materials of Liu et al .. Statistical analysis Data analysis was conducted using R (ver.
51-1	7481-7490	Estimated	_
51-2	7491-7501	underlying	_
51-3	7502-7506	gyri	_
51-4	7507-7510	and	_
51-5	7511-7519	Brodmann	_
51-6	7520-7521	’	_
51-7	7522-7523	s	_
51-8	7524-7529	areas	_
51-9	7530-7533	for	_
51-10	7534-7541	Optodes	_
51-11	7542-7546	1–16	_
51-12	7547-7550	are	_
51-13	7551-7560	described	_
51-14	7561-7563	in	_
51-15	7564-7567	the	_
51-16	7568-7581	Supplementary	_
51-17	7582-7591	Materials	_
51-18	7592-7594	of	_
51-19	7595-7598	Liu	_
51-20	7599-7601	et	_
51-21	7602-7604	al	_
51-22	7605-7607	..	_
51-23	7608-7619	Statistical	_
51-24	7620-7628	analysis	_
51-25	7629-7633	Data	_
51-26	7634-7642	analysis	_
51-27	7643-7646	was	_
51-28	7647-7656	conducted	_
51-29	7657-7662	using	_
51-30	7663-7664	R	_
51-31	7665-7666	(	_
51-32	7667-7670	ver	_
51-33	7671-7672	.	_

Text=3.2.2) and SPSS (ver.
52-1	7673-7678	3.2.2	_
52-2	7679-7680	)	_
52-3	7681-7684	and	_
52-4	7685-7689	SPSS	_
52-5	7690-7691	(	_
52-6	7692-7695	ver	_
52-7	7696-7697	.	_

Text=23.0.0, SPSS Inc.).
53-1	7698-7704	23.0.0	_
53-2	7705-7706	,	_
53-3	7707-7711	SPSS	_
53-4	7712-7716	Inc.	_
53-5	7717-7718	)	_
53-6	7719-7720	.	_

Text=Descriptive demographic and clinical statistics are presented as mean ± standard deviation or as a percentage of cases.
54-1	7721-7732	Descriptive	_
54-2	7733-7744	demographic	_
54-3	7745-7748	and	_
54-4	7749-7757	clinical	_
54-5	7758-7768	statistics	_
54-6	7769-7772	are	_
54-7	7773-7782	presented	_
54-8	7783-7785	as	_
54-9	7786-7790	mean	_
54-10	7791-7792	±	_
54-11	7793-7801	standard	_
54-12	7802-7811	deviation	_
54-13	7812-7814	or	_
54-14	7815-7817	as	_
54-15	7818-7819	a	_
54-16	7820-7830	percentage	_
54-17	7831-7833	of	_
54-18	7834-7839	cases	_
54-19	7840-7841	.	_

Text=An alpha level of α = 0.05 was used as the significance criteria for each test.
55-1	7842-7844	An	_
55-2	7845-7850	alpha	_
55-3	7851-7856	level	_
55-4	7857-7859	of	_
55-5	7860-7861	α	_
55-6	7862-7863	=	_
55-7	7864-7868	0.05	_
55-8	7869-7872	was	_
55-9	7873-7877	used	_
55-10	7878-7880	as	_
55-11	7881-7884	the	_
55-12	7885-7897	significance	_
55-13	7898-7906	criteria	_
55-14	7907-7910	for	_
55-15	7911-7915	each	_
55-16	7916-7920	test	_
55-17	7921-7922	.	_

Text=Differences between clinical scores and demographic metrics were tested using the Welch ’ s t-test except for gender distribution which was assessed using the Chi-square test.
56-1	7923-7934	Differences	_
56-2	7935-7942	between	_
56-3	7943-7951	clinical	_
56-4	7952-7958	scores	_
56-5	7959-7962	and	_
56-6	7963-7974	demographic	_
56-7	7975-7982	metrics	_
56-8	7983-7987	were	_
56-9	7988-7994	tested	_
56-10	7995-8000	using	_
56-11	8001-8004	the	_
56-12	8005-8010	Welch	_
56-13	8011-8012	’	_
56-14	8013-8014	s	_
56-15	8015-8021	t-test	_
56-16	8022-8028	except	_
56-17	8029-8032	for	_
56-18	8033-8039	gender	_
56-19	8040-8052	distribution	_
56-20	8053-8058	which	_
56-21	8059-8062	was	_
56-22	8063-8071	assessed	_
56-23	8072-8077	using	_
56-24	8078-8081	the	_
56-25	8082-8092	Chi-square	_
56-26	8093-8097	test	_
56-27	8098-8099	.	_

Text=Correlations for continuous variables are reported using Spearman ’ s rank correlation coefficients for identified groups as two-tailed test.
57-1	8100-8112	Correlations	_
57-2	8113-8116	for	_
57-3	8117-8127	continuous	_
57-4	8128-8137	variables	_
57-5	8138-8141	are	_
57-6	8142-8150	reported	_
57-7	8151-8156	using	_
57-8	8157-8165	Spearman	_
57-9	8166-8167	’	_
57-10	8168-8169	s	_
57-11	8170-8174	rank	_
57-12	8175-8186	correlation	_
57-13	8187-8199	coefficients	_
57-14	8200-8203	for	_
57-15	8204-8214	identified	_
57-16	8215-8221	groups	_
57-17	8222-8224	as	_
57-18	8225-8235	two-tailed	_
57-19	8236-8240	test	_
57-20	8241-8242	.	_

Text=Correlational analysis for biomarkers was controlled for Family-wise error rate using a channel-wise false discovery rate (FDR).
58-1	8243-8256	Correlational	_
58-2	8257-8265	analysis	_
58-3	8266-8269	for	_
58-4	8270-8280	biomarkers	_
58-5	8281-8284	was	_
58-6	8285-8295	controlled	_
58-7	8296-8299	for	_
58-8	8300-8311	Family-wise	_
58-9	8312-8317	error	_
58-10	8318-8322	rate	_
58-11	8323-8328	using	_
58-12	8329-8330	a	_
58-13	8331-8343	channel-wise	_
58-14	8344-8349	false	_
58-15	8350-8359	discovery	_
58-16	8360-8364	rate	_
58-17	8365-8366	(	_
58-18	8367-8370	FDR	_
58-19	8371-8372	)	_
58-20	8373-8374	.	_

Text=Comparisons between behavioral results and published results presented in the appendix were made using unpaired t-tests.
59-1	8375-8386	Comparisons	_
59-2	8387-8394	between	_
59-3	8395-8405	behavioral	_
59-4	8406-8413	results	_
59-5	8414-8417	and	_
59-6	8418-8427	published	_
59-7	8428-8435	results	_
59-8	8436-8445	presented	_
59-9	8446-8448	in	_
59-10	8449-8452	the	_
59-11	8453-8461	appendix	_
59-12	8462-8466	were	_
59-13	8467-8471	made	_
59-14	8472-8477	using	_
59-15	8478-8486	unpaired	_
59-16	8487-8494	t-tests	_
59-17	8495-8496	.	_

Text=Linear mixed-effects (LME) models were constructed to estimate the effects of task types across subject group as well as clinical covariates on observed behavioral metrics and fNIRS biomarkers.
60-1	8497-8503	Linear	_
60-2	8504-8517	mixed-effects	_
60-3	8518-8519	(	_
60-4	8520-8523	LME	_
60-5	8524-8525	)	_
60-6	8526-8532	models	_
60-7	8533-8537	were	_
60-8	8538-8549	constructed	_
60-9	8550-8552	to	_
60-10	8553-8561	estimate	_
60-11	8562-8565	the	_
60-12	8566-8573	effects	_
60-13	8574-8576	of	_
60-14	8577-8581	task	_
60-15	8582-8587	types	_
60-16	8588-8594	across	_
60-17	8595-8602	subject	_
60-18	8603-8608	group	_
60-19	8609-8611	as	_
60-20	8612-8616	well	_
60-21	8617-8619	as	_
60-22	8620-8628	clinical	_
60-23	8629-8639	covariates	_
60-24	8640-8642	on	_
60-25	8643-8651	observed	_
60-26	8652-8662	behavioral	_
60-27	8663-8670	metrics	_
60-28	8671-8674	and	_
60-29	8675-8680	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
60-30	8681-8691	biomarkers	_
60-31	8692-8693	.	_

Text=LME models offer significant advantages over repeated measures ANOVA in neuroimaging applications as they do not require equal numbers of observations and allow the models to be fit to individual participants.
61-1	8694-8697	LME	_
61-2	8698-8704	models	_
61-3	8705-8710	offer	_
61-4	8711-8722	significant	_
61-5	8723-8733	advantages	_
61-6	8734-8738	over	_
61-7	8739-8747	repeated	_
61-8	8748-8756	measures	_
61-9	8757-8762	ANOVA	_
61-10	8763-8765	in	_
61-11	8766-8778	neuroimaging	_
61-12	8779-8791	applications	_
61-13	8792-8794	as	_
61-14	8795-8799	they	_
61-15	8800-8802	do	_
61-16	8803-8806	not	_
61-17	8807-8814	require	_
61-18	8815-8820	equal	_
61-19	8821-8828	numbers	_
61-20	8829-8831	of	_
61-21	8832-8844	observations	_
61-22	8845-8848	and	_
61-23	8849-8854	allow	_
61-24	8855-8858	the	_
61-25	8859-8865	models	_
61-26	8866-8868	to	_
61-27	8869-8871	be	_
61-28	8872-8875	fit	_
61-29	8876-8878	to	_
61-30	8879-8889	individual	_
61-31	8890-8902	participants	_
61-32	8903-8904	.	_

Text=Models were analyzed using the maximum likelihood (ML) function and degrees if freedom were approximated using Satterthwaite approximation using the R package “ lme4 ”.
62-1	8905-8911	Models	_
62-2	8912-8916	were	_
62-3	8917-8925	analyzed	_
62-4	8926-8931	using	_
62-5	8932-8935	the	_
62-6	8936-8943	maximum	_
62-7	8944-8954	likelihood	_
62-8	8955-8956	(	_
62-9	8957-8959	ML	_
62-10	8960-8961	)	_
62-11	8962-8970	function	_
62-12	8971-8974	and	_
62-13	8975-8982	degrees	_
62-14	8983-8985	if	_
62-15	8986-8993	freedom	_
62-16	8994-8998	were	_
62-17	8999-9011	approximated	_
62-18	9012-9017	using	_
62-19	9018-9031	Satterthwaite	_
62-20	9032-9045	approximation	_
62-21	9046-9051	using	_
62-22	9052-9055	the	_
62-23	9056-9057	R	_
62-24	9058-9065	package	_
62-25	9066-9067	“	_
62-26	9068-9072	lme4	_
62-27	9073-9074	”	_
62-28	9075-9076	.	_

Text=Significance values were thresholded for family error rate using an optode-wise false discovery rate.
63-1	9077-9089	Significance	_
63-2	9090-9096	values	_
63-3	9097-9101	were	_
63-4	9102-9113	thresholded	_
63-5	9114-9117	for	_
63-6	9118-9124	family	_
63-7	9125-9130	error	_
63-8	9131-9135	rate	_
63-9	9136-9141	using	_
63-10	9142-9144	an	_
63-11	9145-9156	optode-wise	_
63-12	9157-9162	false	_
63-13	9163-9172	discovery	_
63-14	9173-9177	rate	_
63-15	9178-9179	.	_

Text=Models here are reported in a similar style to R syntax.
64-1	9180-9186	Models	_
64-2	9187-9191	here	_
64-3	9192-9195	are	_
64-4	9196-9204	reported	_
64-5	9205-9207	in	_
64-6	9208-9209	a	_
64-7	9210-9217	similar	_
64-8	9218-9223	style	_
64-9	9224-9226	to	_
64-10	9227-9228	R	_
64-11	9229-9235	syntax	_
64-12	9236-9237	.	_

Text=LME models for the dependent behavioral metrics of Response Time and SAT-Score were constructed with Task Type, Clinical Group, and Duration as candidate fixed effects and Subject as a random effect with a slope fit for each Block.
65-1	9238-9241	LME	_
65-2	9242-9248	models	_
65-3	9249-9252	for	_
65-4	9253-9256	the	_
65-5	9257-9266	dependent	_
65-6	9267-9277	behavioral	_
65-7	9278-9285	metrics	_
65-8	9286-9288	of	_
65-9	9289-9297	Response	_
65-10	9298-9302	Time	_
65-11	9303-9306	and	_
65-12	9307-9316	SAT-Score	_
65-13	9317-9321	were	_
65-14	9322-9333	constructed	_
65-15	9334-9338	with	_
65-16	9339-9343	Task	_
65-17	9344-9348	Type	_
65-18	9349-9350	,	_
65-19	9351-9359	Clinical	_
65-20	9360-9365	Group	_
65-21	9366-9367	,	_
65-22	9368-9371	and	_
65-23	9372-9380	Duration	_
65-24	9381-9383	as	_
65-25	9384-9393	candidate	_
65-26	9394-9399	fixed	_
65-27	9400-9407	effects	_
65-28	9408-9411	and	_
65-29	9412-9419	Subject	_
65-30	9420-9422	as	_
65-31	9423-9424	a	_
65-32	9425-9431	random	_
65-33	9432-9438	effect	_
65-34	9439-9443	with	_
65-35	9444-9445	a	_
65-36	9446-9451	slope	_
65-37	9452-9455	fit	_
65-38	9456-9459	for	_
65-39	9460-9464	each	_
65-40	9465-9470	Block	_
65-41	9471-9472	.	_

Text=Behavioral models were constructed from the initial models: To simplify the interpretation of the behavioral models, terms removed through the examination of the full model permutations and the optimal model based on the Akaike Information Criterion (AIC) was analyzed.
66-1	9473-9483	Behavioral	_
66-2	9484-9490	models	_
66-3	9491-9495	were	_
66-4	9496-9507	constructed	_
66-5	9508-9512	from	_
66-6	9513-9516	the	_
66-7	9517-9524	initial	_
66-8	9525-9531	models	_
66-9	9532-9533	:	_
66-10	9534-9536	To	_
66-11	9537-9545	simplify	_
66-12	9546-9549	the	_
66-13	9550-9564	interpretation	_
66-14	9565-9567	of	_
66-15	9568-9571	the	_
66-16	9572-9582	behavioral	_
66-17	9583-9589	models	_
66-18	9590-9591	,	_
66-19	9592-9597	terms	_
66-20	9598-9605	removed	_
66-21	9606-9613	through	_
66-22	9614-9617	the	_
66-23	9618-9629	examination	_
66-24	9630-9632	of	_
66-25	9633-9636	the	_
66-26	9637-9641	full	_
66-27	9642-9647	model	_
66-28	9648-9660	permutations	_
66-29	9661-9664	and	_
66-30	9665-9668	the	_
66-31	9669-9676	optimal	_
66-32	9677-9682	model	_
66-33	9683-9688	based	_
66-34	9689-9691	on	_
66-35	9692-9695	the	_
66-36	9696-9702	Akaike	_
66-37	9703-9714	Information	_
66-38	9715-9724	Criterion	_
66-39	9725-9726	(	_
66-40	9727-9730	AIC	_
66-41	9731-9732	)	_
66-42	9733-9736	was	_
66-43	9737-9745	analyzed	_
66-44	9746-9747	.	_

Text=Models were with an AIC score of difference greater than 2 were considered to be statistically different.
67-1	9748-9754	Models	_
67-2	9755-9759	were	_
67-3	9760-9764	with	_
67-4	9765-9767	an	_
67-5	9768-9771	AIC	_
67-6	9772-9777	score	_
67-7	9778-9780	of	_
67-8	9781-9791	difference	_
67-9	9792-9799	greater	_
67-10	9800-9804	than	_
67-11	9805-9806	2	_
67-12	9807-9811	were	_
67-13	9812-9822	considered	_
67-14	9823-9825	to	_
67-15	9826-9828	be	_
67-16	9829-9842	statistically	_
67-17	9843-9852	different	_
67-18	9853-9854	.	_

Text=In order to test the effect of task parameters and clinical status on cerebral hemodynamic biomarkers, [HbO], [Hb], and [Oxy] were assessed as dependent measures in separate LME models.
68-1	9855-9857	In	_
68-2	9858-9863	order	_
68-3	9864-9866	to	_
68-4	9867-9871	test	_
68-5	9872-9875	the	_
68-6	9876-9882	effect	_
68-7	9883-9885	of	_
68-8	9886-9890	task	_
68-9	9891-9901	parameters	_
68-10	9902-9905	and	_
68-11	9906-9914	clinical	_
68-12	9915-9921	status	_
68-13	9922-9924	on	_
68-14	9925-9933	cerebral	_
68-15	9934-9945	hemodynamic	_
68-16	9946-9956	biomarkers	_
68-17	9957-9958	,	_
68-18	9959-9960	[	_
68-19	9961-9964	HbO	_
68-20	9965-9966	]	_
68-21	9967-9968	,	_
68-22	9969-9970	[	_
68-23	9971-9973	Hb	_
68-24	9974-9975	]	_
68-25	9976-9977	,	_
68-26	9978-9981	and	_
68-27	9982-9983	[	_
68-28	9984-9987	Oxy	_
68-29	9988-9989	]	_
68-30	9990-9994	were	_
68-31	9995-10003	assessed	_
68-32	10004-10006	as	_
68-33	10007-10016	dependent	_
68-34	10017-10025	measures	_
68-35	10026-10028	in	_
68-36	10029-10037	separate	_
68-37	10038-10041	LME	_
68-38	10042-10048	models	_
68-39	10049-10050	.	_

Text=Three models were constructed in order to examine the general response to task performance (1), performance sensitivity within the vSAT (2), and the contribution of clinical status to observed activity (3).
69-1	10051-10056	Three	_
69-2	10057-10063	models	_
69-3	10064-10068	were	_
69-4	10069-10080	constructed	_
69-5	10081-10083	in	_
69-6	10084-10089	order	_
69-7	10090-10092	to	_
69-8	10093-10100	examine	_
69-9	10101-10104	the	_
69-10	10105-10112	general	_
69-11	10113-10121	response	_
69-12	10122-10124	to	_
69-13	10125-10129	task	_
69-14	10130-10141	performance	_
69-15	10142-10143	(	_
69-16	10144-10145	1	_
69-17	10146-10147	)	_
69-18	10148-10149	,	_
69-19	10150-10161	performance	_
69-20	10162-10173	sensitivity	_
69-21	10174-10180	within	_
69-22	10181-10184	the	_
69-23	10185-10189	vSAT	_
69-24	10190-10191	(	_
69-25	10192-10193	2	_
69-26	10194-10195	)	_
69-27	10196-10197	,	_
69-28	10198-10201	and	_
69-29	10202-10205	the	_
69-30	10206-10218	contribution	_
69-31	10219-10221	of	_
69-32	10222-10230	clinical	_
69-33	10231-10237	status	_
69-34	10238-10240	to	_
69-35	10241-10249	observed	_
69-36	10250-10258	activity	_
69-37	10259-10260	(	_
69-38	10261-10262	3	_
69-39	10263-10264	)	_
69-40	10265-10266	.	_

Text=In the first model, the presence of group differences during task performance was estimated using Task Type, Score, and Clinical Group as fixed effects: In the second model, the relationship between cerebral hemodynamics during the vSAT and individualized susceptibility to attentional modulation was assessed using Score Difference and Group as fixed effects: In the third model, we examined the influence of clinical status using Task-Type and total PANSS score as fixed effects: Selected fNIRS spatial parametric maps are presented using the calculated F-statistics and thresholded using statistical significance for visualization purposes for individual model parameters.
70-1	10267-10269	In	_
70-2	10270-10273	the	_
70-3	10274-10279	first	_
70-4	10280-10285	model	_
70-5	10286-10287	,	_
70-6	10288-10291	the	_
70-7	10292-10300	presence	_
70-8	10301-10303	of	_
70-9	10304-10309	group	_
70-10	10310-10321	differences	_
70-11	10322-10328	during	_
70-12	10329-10333	task	_
70-13	10334-10345	performance	_
70-14	10346-10349	was	_
70-15	10350-10359	estimated	_
70-16	10360-10365	using	_
70-17	10366-10370	Task	_
70-18	10371-10375	Type	_
70-19	10376-10377	,	_
70-20	10378-10383	Score	_
70-21	10384-10385	,	_
70-22	10386-10389	and	_
70-23	10390-10398	Clinical	_
70-24	10399-10404	Group	_
70-25	10405-10407	as	_
70-26	10408-10413	fixed	_
70-27	10414-10421	effects	_
70-28	10422-10423	:	_
70-29	10424-10426	In	_
70-30	10427-10430	the	_
70-31	10431-10437	second	_
70-32	10438-10443	model	_
70-33	10444-10445	,	_
70-34	10446-10449	the	_
70-35	10450-10462	relationship	_
70-36	10463-10470	between	_
70-37	10471-10479	cerebral	_
70-38	10480-10492	hemodynamics	_
70-39	10493-10499	during	_
70-40	10500-10503	the	_
70-41	10504-10508	vSAT	_
70-42	10509-10512	and	_
70-43	10513-10527	individualized	_
70-44	10528-10542	susceptibility	_
70-45	10543-10545	to	_
70-46	10546-10557	attentional	_
70-47	10558-10568	modulation	_
70-48	10569-10572	was	_
70-49	10573-10581	assessed	_
70-50	10582-10587	using	_
70-51	10588-10593	Score	_
70-52	10594-10604	Difference	_
70-53	10605-10608	and	_
70-54	10609-10614	Group	_
70-55	10615-10617	as	_
70-56	10618-10623	fixed	_
70-57	10624-10631	effects	_
70-58	10632-10633	:	_
70-59	10634-10636	In	_
70-60	10637-10640	the	_
70-61	10641-10646	third	_
70-62	10647-10652	model	_
70-63	10653-10654	,	_
70-64	10655-10657	we	_
70-65	10658-10666	examined	_
70-66	10667-10670	the	_
70-67	10671-10680	influence	_
70-68	10681-10683	of	_
70-69	10684-10692	clinical	_
70-70	10693-10699	status	_
70-71	10700-10705	using	_
70-72	10706-10715	Task-Type	_
70-73	10716-10719	and	_
70-74	10720-10725	total	_
70-75	10726-10731	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
70-76	10732-10737	score	_
70-77	10738-10740	as	_
70-78	10741-10746	fixed	_
70-79	10747-10754	effects	_
70-80	10755-10756	:	_
70-81	10757-10765	Selected	_
70-82	10766-10771	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
70-83	10772-10779	spatial	_
70-84	10780-10790	parametric	_
70-85	10791-10795	maps	_
70-86	10796-10799	are	_
70-87	10800-10809	presented	_
70-88	10810-10815	using	_
70-89	10816-10819	the	_
70-90	10820-10830	calculated	_
70-91	10831-10843	F-statistics	_
70-92	10844-10847	and	_
70-93	10848-10859	thresholded	_
70-94	10860-10865	using	_
70-95	10866-10877	statistical	_
70-96	10878-10890	significance	_
70-97	10891-10894	for	_
70-98	10895-10908	visualization	_
70-99	10909-10917	purposes	_
70-100	10918-10921	for	_
70-101	10922-10932	individual	_
70-102	10933-10938	model	_
70-103	10939-10949	parameters	_
70-104	10950-10951	.	_

Text=Statistical significance of model fixed effects was assessed using the Satterthwaite approximation for degrees of freedom.
71-1	10952-10963	Statistical	_
71-2	10964-10976	significance	_
71-3	10977-10979	of	_
71-4	10980-10985	model	_
71-5	10986-10991	fixed	_
71-6	10992-10999	effects	_
71-7	11000-11003	was	_
71-8	11004-11012	assessed	_
71-9	11013-11018	using	_
71-10	11019-11022	the	_
71-11	11023-11036	Satterthwaite	_
71-12	11037-11050	approximation	_
71-13	11051-11054	for	_
71-14	11055-11062	degrees	_
71-15	11063-11065	of	_
71-16	11066-11073	freedom	_
71-17	11074-11075	.	_

